UFT plus carboplatin for head and neck cancer.

Abstract

Cisplatin plus fluorouracil (5-FU) is widely accepted as neoadjuvant and adjuvant chemotherapy in the treatment of head and neck squamous cell carcinoma; UFT is also an active agent against this disease. In the first retrospective study, we examined the efficacy of UFT as adjuvant chemotherapy in patients with maxillary cancer. The 5-year survival rate of those treated with UFT vs those not treated was 71.4% vs 23.8%, respectively. In the second study we developed the carboplatin plus UFT regimen--as a modification of cisplatin plus 5-FU--and studied its efficacy and toxicity in patients with advanced head and neck squamous cell carcinoma. These patients received UFT plus carboplatin. The objective response rate was 53.1%; grade > or = 3 leukopenia, anemia, and thrombocytopenia were rare. These findings suggest that UFT plus carboplatin in the outpatient setting is feasible for patients with head and neck squamous cell carcinoma.

• Authors: M Fujii, Y Ohno, Y Tokumaru, Y Imanishi, M Kanke, T Tomita, T Yamashita
• Journal: Oncology (Williston Park, N.Y.) (Oncology (Williston Park)) Vol. 14 Issue 10 Suppl 9 Pg. 72-5 (Oct 2000) ISSN: 0890-9091 [Print] United States
• PMID: 11098499 (Publication Type: Clinical Trial, Journal Article)

Chemical References

• Antineoplastic Agents
• Tegafur
• Uracil
• Carboplatin

Topics

• Administration, Oral
• Antineoplastic Agents (administration & dosage, therapeutic use)
• Antineoplastic Combined Chemotherapy Protocols (administration & dosage, therapeutic use)
• Carboplatin (administration & dosage, therapeutic use)
• Carcinoma, Squamous Cell (drug therapy, pathology)
• Chemotherapy, Adjuvant
• Drug Therapy, Combination
• Humans
• Maxillary Sinus Neoplasms (drug therapy, pathology)
• Survival Analysis
• Tegafur (administration & dosage)
• Treatment Outcome
• Uracil (administration & dosage)